GLP-1R agonists are licensed by the US Food and Drug Administration (FDA) for the treatment of T2DM; however, these agents are currently extensively studied as novel PD-modifying agents that can have an impact on multiple mechanisms of PD pathology. Here, GLP1R is linked to Parkinson disease.